G

George R. Blumenschein

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-9606-8194

724 papers and 42.4k citations.

PubIndex Score98Top 2%How it's scored

724Publications

42.4kTotal Citations

First senior author: 1974

Top publicationsby citations

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|New England Journal of Medicine|2016

Cited by 5.1k

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Daniel R. Gomez, John V. Heymach, Chad Tang et al.|Journal of Clinical Oncology|2019

Cited by 1.3k

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Daniel R. Gomez, John V. Heymach, Ritsuko Komaki et al.|The Lancet Oncology|2016

Cited by 1.1k

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Oral Oncology|2018

Cited by 802

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Kevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017

Cited by 431

Indexing the rest of 724 publications…